Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price dropped 16.7% during trading on Saturday . The company traded as low as C$0.10 and last traded at C$0.10. Approximately 670,435 shares changed hands during mid-day trading, an increase of 78% from the average daily volume of 376,657 shares. The stock had previously closed at C$0.12.
Hemostemix Trading Down 16.7%
The firm has a market capitalization of C$14.57 million, a PE ratio of -2.92 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The company’s 50-day simple moving average is C$0.13 and its 200 day simple moving average is C$0.15.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 07/28 – 08/01
- Stock Market Upgrades: What Are They?
- Will Hims & Hers Fall Along With Novo Nordisk?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
